As a long time investor in ACHN, I like your call. I do know there's a lot of pending news due out soon -- (1) ACH 3422 trial results in GT2 and GT3, (2) Sparta trials on 3422/3102 doublet 12/8/6 week treatment starting in June, (3) new tablet formulations for all 3 agents (3422, 3102, sovaprevir) for ease of use by patients, (4) competitor's drug regimens not faring so well for 6 week treatment, ... and many other items, which we will hear about in due course. It's all good!
What are your thoughts on something great for ACHN?
You did mention a possible GILD buyout. I see a buyout by any of the other Hep C players (MRK or ABBV or BMY or J&J) being equally likely.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM